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Circulating and mesangial secretory component-binding IgA-i in pri-
mary IgA nephropathy. in a prospective study of 38 patients who
presented with hematuria of renal origin, 15 patients were found to have
primary IgA nephropathy and 23 had other renal disorders. Sera and
renal biopsy specimens of these patients were studied for the presence
of macromolecular IgAl and lgA2 using monoclonal antibodies, and the
presence of J-chain as demonstrated either by immunofluorescence or
its capacity to bind free secretory component. Circulating macromo-
lecular lgA was found exclusively in the sera of patients (80%) with
primary IgA nephropathy. In these sera the polymer/monomer ratio for
igAl (0.64 was significantly higher than for normal human
serum (0.39 (P < 0.001), while no differences were found for
lgA2. The polymeric IgAl was isolated from serum by gel chromatog-
raphy and was shown to have the capacity to bind free secretory
component. Direct two-color immunoliuorescence studies revealed the
presence of only IgAl in the mesangial deposits and also its capacity to
bind free secretory component. We conclude (1) that demonstration of
circulating macromolecular igA in patients with renal hematuria is of
diagnostic value and (2) that antigenetic similarities between the circu-
lating and the mesangial macromolecular IgA suggest that dimeric IgAl
is deposited in the mesangium of patients with primary IgA nephrop-
athy.
Piece sécrétoire liant I'IgA-l circulante et mesangiale au cours de Ia
néphropathie a IgA primitive. Dans une étude prospective de 38 malades
ayant présenté une hématurie d'origine rénale, IS malades avaient une
néphropathie a IgA primitive, et 23 avajent d'autres maladies rénales.
Dans les serums et les specimens de biopsies rénales de ces malades on
a cherché Ia presence d'IgA-l et IgA-2 macromoléculaires avec des
anticorps monoclonaux et La presence de chaines J démontrées soit par
immunofluorescence, soit par sa capacitC a se her a Ia pièce sCcrétoire
libre. Dc l'IgA macromolécuhaire circulante a Cté trouvée exclusive-
ment dans les serums de malades (80%) atteints de nephropathie a IgA
primitive. Dans ces serums le rapport polymere/monomère pour l'lgA-l
(0,64 0,13) Ctait significativement plus élevé que celui du serum
humain normal (0,39 0,01) (P <0,001), alors qu'on n'a pas trouvé de
difference pour IgA-2. L'IgA-t pohymerique a Cté isolée a partir du
serum par chromatographie sur gel et on a montré queue était capable
de se her a ha pièce sécrétoire hibre. Des etudes d'inimunofiuorescence
directe a deux couleurs ont révélé Ia presence d'lgA-l seulement dans
es depots mésangiaux et également sa capacité 0 se her a ha pièce
sécrétoire libre. Nous concluons que (I) Ia demonstration d'IgA
macromoléculaire circulante chez des malades présentant une
hématurie rénale possède une valeur diagnostique et (2) les similarités
antigéniques entre hes IgA circulante et mesangiale suggèrent que de
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I'lgA-t dimérique se depose dans le unésangium de malades atteints de
néphropathie a IgA primitive.
The hallmark of primary IgA nephropathy is the finding of
mesangial deposits of immunoglobulin A [1—3]. Circulating
macromolecular IgA has been demonstrated recently, either as
a polymer or as an immune complex, in patients with primary
IgA nephropathy [4—7]. Similarities, if any, between the circu-
lating and the mesangial macromolecular IgA could suggest a
pathogenetic relationship. Attempts to characterize the mesan-
gial IgA have led to conflicting results as far as the subclasses of
IgA [6, 8—lI], the presence of J-chain [8, ii, 12—14], and the
capacity of this IgA to bind free secretory component [12, 15]
are concerned. The circulating macromolecular IgA has not
been characterized except for its size which ranges between lOS
and 21S [4, 6, 7].
Therefore, we studied mesangial IgA and circulating
macromolecular IgA by means of immunofluorescence and
immunochemical techniques using monoclonal antibodies
against the subclasses of IgA; the presence of 'true" dimeric
IgA was demonstrated by their size and ability to bind free
secretory component. Furthermore, a prospective study was
carried out to determine whether the presence of circulating
macrotnolecular IgA is a specific finding for patients presenting
with renal hematuria due to primary IgA nephropathy.
Methods
Patients
Thirty-eight patients, referred to our Nephrology Clinic be-
tween January 1981 and August 1982, were eligible for a
prospective study on the basis of the following criteria: micro-
or macrohematuria (> 10 erythrocytes per high power field),
24-hr urinary protein excretion less than 0.5 g, normal cre-
atinine clearance, normal blood pressure, and no evidence of
extrarenal disease; negative or normal intravenous pyelog-
raphy, cystoscopy, tests for antinuclear antibody, rheumatoid
factor (Rose-Waaler and Latex fixation), hepatitis B antigen,
cryoglobulins, and liver function tests. In each case a
percutaneous renal biopsy, two biopsies of normal appearing
skin from the inner surface of the upper arm, and a serum
sample were taken on the same day. Serial blood samples,
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taken at follow-up, were immediately frozen in aliquots at
—70°C until tested. All serological and histopathological studies
were performed in a double blind fashion.
Immune complex assays, complement, and immunoglobulin
determinations
The '251-Clq binding assay (C1qBA), the congiutinin-binding
assay (ConBA) using heavy chain-specific antibodies against
IgG, IgA, and 1gM, and the anti-IgA inhibition binding assay
(a-IgA-InhBA) were performed as previously described 171.
Complement (CIq, C4, C3) and serum immunoglobulin (IgG,
IgA, 1gM) levels were determined by double radial immunodif-
fusion and CH5O levels by the method of Mayer [16]. Properdin
and the complement breakdown product C3d were determined
by rocket electrophoresis, as described elsewhere [17].
Properdin levels were expressed using a standard of purified
properdin, isolated according to the method of Fearon and
Austen [18]. Hemolytic titration of Clq was performed accord-
ing to published methods [19]. The following levels are normal
for our laboratory: CH5O 256 to 580 U/liter; C3 68 to 104 mg%;
C4 17 to 30 mg%; Clq 10 to 14 mg%; C3d 4.7 to 13.9 g/ml;
properdin 17.1 to 27.7 g/ml; IgG 8.3 to 15.8 mg/mi; IgA 1.1 to
4.0 mg/mi; 1gM 0.2 to 1.8 mg/ml.
Antibody preparations and SC isolation
Antisera against human lgG, polycional IgA, C3, and factor
H were raised by immunization of rabbits with the respective
purified proteins. Antisera against human 1gM, C4, and factor B
were raised in goats and the anti-Clq serum in sheep. Anti-IgG
and anti-IgA antisera were rendered y and a chain-specific by
absorption to (Fab')2-fragments of normal human IgG bound to
Biogel AS adsorbent. All antisera were monospecific according
to immunoelectrophoresis and Ouchterlony analysis. IgG frac-
tions of these antisera were conjugated with fluorescein accord-
ing to a standard method [20]. Antisera directed against secre-
tory component and J-chain were purchased from Nordic
Laboratories (Tilburg, The Netherlands). The antibodies with
specificity for both IgA subclasses are designated anti-IgA-
common.
Mouse monoclonal antibodies against isotypic determinants
of human IgAl and IgA2 subclasses were prepared by the
method of KOhler and Milstein [21]. In brief, spleen cells from
BALB/c mice, immunized intraperitoneally with alum-
precipitated purified human IgAl-A and IgA2-k paraproteins,
were hybridized with SP 2/0 myeloma cells [22]. Antibody-
secreting cultures were selected with an ELISA technique on
the basis of their capacity to bind to IgA coated onto plastic
wells and a peroxidase-labeled goat antiserum against mouse
immunoglobulins (Nordic Laboratories, Tilburg, The Nether-
lands). The specificity of the monoclonal antibodies was
checked with a panel of 11 different IgAl paraproteins and five
different IgA2 paraproteins. Both series included kappa and
lambda proteins. Within the IgA2 set, one paraprotein carried
the Am2 allotype and the other four did not. Two monoclonal
antibodies were eventually selected and used for this study:
clone 69-11.4 that reacts only with IgAl and clone 16-5l2-H5
that reacts only with IgA2. The specificity was confirmed by
radioimmunoassay (indirect binding assay and competition RIA
using labeled antigen and plastic-adsorbed antibody) and
hemagglutination assay. Clones were propagated in mouse
peritoneal cavities. Ascitic fluids were tested by polyethylene
glycol-enhanced immunodiffusion analysis. Precipitation was
observed with dimeric forms of IgAs of the appropriate
subclass. No light chain or allotype preference was noted. The
respective antibodies were purified from ascitic fluid by Protein-
A chromatography [23] and conjugated with fluorescein or
rhodamine [201. The conjugates were then tested using normal
bone marrow specimens and bone marrow from IgA myeloma
patients by a two-color immunofluorescence procedure. The
two antibodies stained two different populations of cells in
normal bone marrow. In ten IgAl myeloma bone marrow
preparations only 69-11.4 produced staining. The cells of the
single IgA2 myeloma bone marrow specimen available for the
testing of 16-512-H5 stained with this antibody and not with the
anti-IgAl conjugate(s). Both 69-11.4 and l6-5l2-H5 belong to
the mouse IgGl subclass, as determined by immunodiffusion
with polyclonal antisera monospecific for mouse immunoglob-
ulin isotypes [241.
Free secretory component (SC) was isolated, as described
previously [25]. One part of this preparation was labeled with
FITC for immunofluorescence studies, the rest was used for
SC-binding studies.
Chromatography
Gel filtration was performed by applying 1 ml serum on a 90
x 1.5 cm column containing Sephadex-300 superfine
(Pharmacia, Zoetermeer, The Netherlands) equilibrated with
phosphate-buffered saline containing 0.002 M EDTA, pH 7.4;
elution was performed with the same buffer. Fractions of 1.4 ml
each were collected. The filtration volumes of monomeric IgA
and pentameric 1gM, determined by radial immunodiffusion,
and Clq (hemolytic titration) served as molecular weight mark-
ers. The column fractions were tested for the presence of IgAl
and IgA2 subclasses by an ELISA assay and for their capacity
to bind free secretory component by a radioimmunoassay.
ELISA assay for IgA] and IgA2
Microtitration plates were incubated with the anti-
IgA-common antiserum in 0.1 M sodium bicarbonate, pH
9.6, containing 0.02% NaN3. Unoccupied binding sites were
saturated with bovine serum albumin; each step in the assay
was followed by extensive washing with PBS. One hundred
microliters of the test samples were incubated in the wells for 60
mm at 37°C; subsequently, 100 1.d of the monoclonal antibody
against IgA-l or IgA-2 were added and incubation was contin-
ued for 45 mm at 37°C. In the next step horse radish peroxidase-
conjugated rabbit antimouse IgG antiserum (Nordic Laborato-
ries, Tilburg, The Netherlands) was added and left to incubate
for 45 mm at 37°C. Finally the substrate ortho-phenelyne
diamine in 0.2 M phosphate buffer containing 0.1 M citrate, pH
5.0, was added. One hour later the color reaction was measured
spectrophotometrically at 492 nm. The specificity of this assay
was confirmed by using isolated human IgA-1 and IgA-2
myeloma proteins; the assay detected levels of IgA- I and IgA-2
as low as 4.4 and 3.3 ng/ml, respectively. Optimal dilutions in
PBS of the antibody preparations and the column fractions were
determined to obtain a maximum working range. The results for
the fractionated sera were expressed as the optical density
readings and as the polymer/monomer ratio; the latter was
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obtained by dividing the observed optical density for the
fraction representing the molecular weight of dimeric IgA by
the value obtained for the monomeric IgA fraction.
SC-binding assay
Isolated free SC was adsorbed passively to microtitration
plates, followed by phosphate-buffered saline (PBS) containing
1% bovine serum. Individual column fractions were added to
the wells, and the binding of IgAl or IgA2 was measured by
means of '251-labeled monoclonal anti-IgAl and anti-IgA2,
respectively, and a gamma counter. The monoclonal antibodies
were iodinated, using iodo-beads [261 as an oxidative agent.
Myeloma sera, containing a high concentration of lOS IgAl or
IgA2, served as positive controls. The results were expressed in
counts per minute.
Biopsies
Renal and skin tissue samples were prepared for light micros-
copy studies as described previously [7, 271. For direct im-
munofluorescence studies fresh-frozen sections of 2-ri thick-
ness were air-dried and fixed in ether-alcohol and incubated
with fluorescein-conjugated antibodies specific for human IgG,
IgA-common, 1gM, C3, and C4. In addition, renal sections were
also examined for the presence of factors B and H, secretory
component and J-chain. Furthermore, renal sections were also
pretreated with 6 M urea in glycine-HC1 (pH 3.2) for 30 mm, to
facilitate the detection of J-chain [28]. Renal biopsy specimens
with a positive anti-IgA-common stain were examined for
two-color direct immunofluorescence using rhodamine-con-
jugated monoclonal mouse antibodies against human IgAl or
IgA2 subclasses and fiuorescein-conjugated antibodies against
IgA-common. Furthermore, tissue sections were incubated
with fluorescein-conjugated purified free human secretory com-
ponent and subsequently with rhodamine-conjugated antibodies
against IgAl. Slides were examined under a Zeiss microscope
equipped for selective visualization of the two fluorochromes.
Primary IgA nephropathy was defined by the presence of
mesangial deposits of predominantly IgA, with or without other
immunoglobulins or complement components, in combination
with a light microscopic pattern ranging from normal to mesan-
gial proliferation, without capillary wall lesions suggestive of
other glomerulopathies.
Results
Renal and skin biopsies
Fifteen of the 38 patients with renal hematuria had primary
IgA nephropathy according to the results of renal biopsy studies
(group 1); the mesangial deposits from three patients contained
exclusively IgA, while the remaining 12 biopsy specimens also
exhibited C3. This was accompanied in three patients by 1gM,
in one patient by IgG, and in another patient by IgG with 1gM.
The other 23 patients (group 2) had a variety of renal diseases
including 1gM nephropathy (three patients), nephrosclerosis
(five patients), intracapillary proliferative glomerulonephritis
(nine patients), and extracapillary glomerulonephritis (one pa-
tient) or normal findings (five patients). Mesangial deposits of
C3 alone were found in six biopsy specimens; in 13 of the 23
patients the immunofluorescence findings were negative.
Glomerular deposits of IgA were absent in all patients of group
2. Factors B and H could not be demonstrated in any of the 38
renal biopsy specimens.
In skin biopsy specimens vascular deposits of IgA were found
for four (26%) patients with primary IgA nephropathy and three
patients (13%) of group 2. Deposits of 1gM were demonstrated
in two and three patients irom these groups, respectively. In
two patients, 1gM was found in the skin but not in the renal
biopsy. In both groups one patient had deposits of C3 in the
skin. Immunofluorescent staining of the skin biopsy specimens
was therefore completely negative for eight patients with IgA
nephropathy and 16 patients of group 2. Light microscopy
studies revealed no abnormalities in any of the 38 skin biopsy
specimens.
Characterization of mesangial IgA deposits
Thirteen of the 15 biopsy specimens could be used for
complete characterization of the mesangial IgA. Two-color
immunofluorescence examination revealed IgAl determinants
with a distribution pattern identical to that of IgA-common
determinants in 12 biopsy specimens. Mesángial IgA2 could not
be detected in any of the cases (see Table 1). One patient (no.
9) had positive immunofluorescence with anti-IgA-common, but
not with anti-IgAl or anti-IgA2. In most cases staining was
found in some of the renal tubular cells for IgAl and, to a lesser
extent, for IgA2. Two-color immunofluorescence studies
showed that the distribution pattern of the binding of fluoro-
chrome-conjugated free secretory component was identical to
that of rhodamine-tagged anti-IgAl for 11 of the 12 patients with
positive IgAl immunofluorescence. Antisera against secretory
component and i-chain yielded negative results for all biopsies.
However, after preincubation of renal tissue from nine patients
with 6 M urea in glycine-HC1, all showed a positive mesangial
staining with the anti-i-chain antiserum.
Characterization of macromolecular material
in the circulation
The results of the immune complex assays for the serum
samples obtained on the same day as the renal biopsy specimen
are shown in Table 2. Twelve (80%) of the 15 patients with
primary IgA nephropathy (group 1) had a positive ts-IgA-InhBA
whereas all patients of group 2 had a negative a-IgA-InhBA.
With the CIqBA all serum samples were negative, while 30% of
the patients from each group had a positive ConBA. When the
follow-up serum samples (158 sera, mean 4.2 per patient) were
examined, the sera of the three patients of group 1 with a
negative cx-IgA-lnhBA remained negative, despite persistent
hematuria. Eight of the remaining 12 patients with a positive
a-IgA-InhBA had persistent hematuria during follow-up and all
serum samples gave consistently positive results. In four pa-
tients of group 1 the heniaturia was intermittent and only those
serum samples taken during hematuria produced a positive
a-IgA-InhBA. The results of the a-IgA-InhBA remained nega-
tive for all the patients of group 2 throughout the follow-up
period.
For 11 of the 12 patients with a positive ci-IgA-InhBA, this
test was positive only when whole serum was used (Table 1).
The test was negative with the precipitate of serum in 3.5%
PEG, indicating that the size of the reactive IgA was smaller
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Table 1. Characterization of mesangial and circulating IgA for 15 patients with primary IgA nephropathy
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ial IgA
Serum IgA
Mesang a-IgA-InhBA
IOS/7S ratio SC-binding MonomericPatient IgA- SC- PEG Whole
no. common lgA-1 IgA-2 binding precipitate serum for IgAl for IgA-1 serum IgA
1 + + — + — -i- ++ t
2 + NT NT NT — — = — N
3 + + — + — + I ++ N
4 -1- + — + — + ++ N
5 + + — + — + I ++ I
6 + + — + — + I --+ I
7 + + — + — + I ++ N
8 + + — — — — = — N
9 + — — — + — I ++ N
10 + + — + — — = — N
11 + NT NT + — + +
12 + + — + — + + N
13 + + — + — + + I
14 + + — + — + I — N
15 + + — + — + I ++ N
Abbreviations: NT denotes not tested and N denotes normal.
IgA ne-
phropathy 15 12 0 5 4 3
Other renal
diseases 23 0 0 6 5 7
Abbreviations: a-IgA-InhBA denotes n-IgA inhibition binding assay;
C1qBA, '251-Clq binding assay; ConBA, conglutinin binding assay.
than 21S [291. For one patient (no. 9), the a-IgA-InhBA was
positive only when the PEG precipitate of serum was used.
Sera from all 15 patients with primary IgA nephropathy and
five normal human sera (NHS) were separated according to size
by gel filtration using Sephadex-300 and the fractions were
tested for the presence of IgAl and IgA2 using the subclass-
specific monoclonal antibodies in an ELISA assay. For the 12
patients with a positive a-IgA-InhBA, more IgAl was found in
the fractions corresponding with the molecular weight of
dimeric IgA than for NHS. The elution profile as found for these
12 patients with primary IgA nephropathy is illustrated by a
typical example for a patient (no. 3) and for NHS in Figure 1.
The mean range of polymeric IgAl, expressed as optical density
readings (0D492), found for the 12 patients, was 184 47 and
for monomeric IgAl, 289 40. The mean range of polymeric
IgAl for all normal human sera was 107 45 and for mono-
meric IgAl 269 62. To exclude the possibility of proportional
changes between the amounts of polymeric and monomeric IgA
in serum we related the result of the ELISA assay for polymeric
(lOS) IgA to that for monomeric (7S) IgA. The mean
polymer/monomer ratio (see Methods) for IgAl for the patients
with primary IgA nephropathy was significantly higher (0.64
0.13) than that for NHS (0.39 0.01) (P < 0.001). For the three
patients with a negative a-IgA-InhBA the polymer/monomer
x
0—n/ x7/ 00 L//19-- I I I I r
32 36 40 44 48 52 56 60
Frection numbers
Fig. 1. Gel chromatography of serum from a patient with primary IgA
nephropathy (0—0) and normal human serum (x --- x). Shown are the
results of the optical density readings determined by an ELISA-assay
for IgAl. Arrowheads indicate the filtration volumes of 1gM, Clq, and
IgA determined in the fractions of both sera.
ratio for IgAl did not differ from that for NHS. For IgA2, no
differences in the amount or distribution of IgA2 in the column
fractions were found between patient sera and NHS. The mean
range of polymeric IgA2 found for the 12 patients was 175 43
and for monomeric IgA2 195 34. For NHS these findings
were 133 57 and 164 76, respectively. Furthermore, the
mean (± SD) polymer/monomer ratio for IgA2 found for the 15
patients with primary IgA nephropathy did not differ from that
for NHS (0.9 0.01 and 0.86 0.08, respectively). The
findings for IgAl and IgA2 for the patients for the control group
did not differ from those found for NHS.
The results of the experiments to determine the capacity of
polymeric IgA to bind free secretory component are shown in
Figure 2. A statistically significant increase in the amount of
polymeric IgAl capable of binding free SC was found for 11
Table 2. Results of immune complex assays for 38 patients with
hematuria of renal origin
Total ConBA
number cs-IgA- -____________________
of patients InhBA CIqBA Anti-y Anti-s Anti-p
500 -
400 -
300 -
V V
1gM Clq
(NC)
V
IgA
200 —
100 -
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Fig. 2. Secretory component-binding capacity of polymeric IgAl and
IgA2. Sera from 15 patients with primary IgA nephropathy (lgA-N) and
five normal subjects (NHS) were first subjected to gelfiltration and the
peak fractions containing polymeric IgA for each serum were subse-
quently assessed for their SC-binding capacity.
patients when compared to that for NHS (mean 2260 1266 vs.
899 400 cpm). The four patients with normal results included
the three patients with a negative a-IgA-InhBA and one ad-
ditional patient with a positive a-IgA-InhBA (no. 14), a result
that remains unexplained. The secretory component-binding
capacity of polymeric lgA2 did not differ between patients and
NHS (mean 139 40 and 132 41 cpm, respectively).
The combined results of the characterization of circulating
IgA and mesangial IgA (see Table 1) indicate the presence of
secretory component-binding IgAl in the mesangium and
a surplus of this material, presumably dimeric IgAl, in
the circulation of most of our patients with primary IgA
nephropathy.
Complement and immunoglohulin levels
Normal CH5O, C3, C4, and Clq levels were found for all
patients with primary IgA nephropathy. Low levels of C4 were
demonstrated for two patients with 1gM nephropathy, two with
only C3 deposits, and one additional patient. Properdin levels
were slightly below normal for one patient from group 1 (14.5
tg/ml) and three patients (12.5, 14.5, and 14.5 tg/ml) from
group 2. C3d levels were within the normal range for all
patients.
Levels of IgA were elevated in five patients (30%) with IgA
nephropathy (5.1, 7.2, 7.2, 9.4, and 5.0 mg/ml). The mean level
of serum IgA for the remaining ten patients was 2.8 1.1
mg/mi. No significant differences between the two groups of
patients in the mean serum level of IgG (13.3 3.6 and 14.0
3.6 mg/ml, respectively) and 1gM (1.4 1.1 and 1.4 0.9
mg/ml, respectively) were found.
Discussion
Of all patients presenting with hematuria as the sole clinical
manifestation of renal disease, less than 50% will have primary
IgA nephropathy [7]. In this prospective study of 38 patients
with exclusively renal hematuria, primary igA nephropathy was
found in 15 patients, while 23 patients had other renal disorders.
In the latter group, six patients had mesangial deposits of C3
only, as described by Orfilla [30, 311, and three patients had
1gM nephropathy [32], which has been associated with protein-
uria but may also present with hematuria [33]. Deposits of
mesangial IgA recur in renal transplant patients [34, 35] and
disappear from transplanted kidneys with IgA deposits [36, 37].
This suggests that a circulating factor is involved in the patho-
genesis of primary IgA nephropathy.
In a recent retrospective study we demonstrated the presence
of circulating macromolecular IgA, as detected by the anti-IgA
inhibition binding assay (n-IgA-InhBA), in patients with pri-
mary IgA nephropathy [7]. The current prospective study
shows that a positive a-IgA-InhBA distinguishes between pa-
tients with primary IgA nephropathy and those with other renal
lesions presenting with hematuria. Such a distinction could not
be based on the results of skin biopsy studies, complement
determinations, the C1qBA or the ConBA. Immune complexes
which bind Ciq were absent, as in most cases of primary
glomeruionephritis [38]. Conglutinin-binding immune com-
plexes were found in 30% of the patients from both groups. This
incidence among patients with primary IgA nephropathy is in
agreement with the findings of others [15, 39, 401, although
these latter studies did not include a control group of patients
with other renal diseases—which precluded demonstration of
the nonspecificity of such findings. Eighty percent of our
patients with primary IgA nephropathy have macromolecular
IgA in their circulation. The finding of macromolecular IgA in
sera of patients with renal hematuria strongly supports the
diagnosis of primary IgA nephropathy, but the absence of this
material does not exclude such a diagnosis. This might be
explained by the sensitivity of the cs-IgA-InhBA, the degree of
hematuria [71 or another still unknown pathophysiological
mechanism.
Several investigators have demonstrated macromolecular
IgA or immune complexlike material containing IgA in patients
with primary IgA nephropathy [4—6]; the sizes range from lOS
to 21S [4, 6, 7]. The macromolecular IgA detected with the
a-IgA-InhBA, when whole serum gives positive results and the
PEG precipitate is negative, is smaller than 21S [291. The
characteristics of this IgA were analyzed by gel chromatogra-
phy for all our patients with primary IgA nephropathy. All sera
with a positive cs-IgA-InhBA contained an increased amount of
polymeric IgA i—the size being the same as that of dimeric
IgA—compared to the amount found in NHS. Although the
amount of polymeric IgA in serum could be independent of the
amount of monomeric IgA [41], the possibility of such a
relationship was further excluded by relating the reactivity in
the ELISA assay of lOS IgA to that of 7S IgA (poiymer/
monomer ratio). An increased IgAl polymer/monomer ratio
was found for patients with primary IgA nephropathy compared
to that found for NHS. The three patients who did not show
circulating macromolecular IgA (negative a-IgA-InhBA) had a
normal polymer/monomer ratio. The true dimeric nature of the
polymeric IgAl isolated from serum was shown by its capacity
to bind free secretory component, with the exception of one
patient (no. 14). Conflicting results have been published con-
cerning the subclasses of the IgA found in the mesangium: IgAl
[6, 8, ii], IgA2 [9], and both subclasses 19] have been reported.
The finding of mesangial IgA2 deposits by André et al [9] has
been questioned [101 and could be caused by the use of antisera
of insufficient specificity or indirect immunofluorescence tech-
niques that may produce nonspecific staining. In addition,
reports on the presence of i-chain [8, 11—131 and secretory
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component [12, 13, 42—45] as well as the secretory component-
binding capacity [12, 15] are often contradictory. In the present
study all of these aspects were studied using the same subclass-
specific monoclonal antibodies as were used for characteriza-
tion of the circulating IgA. Deposits of IgAl only were found in
the mesangium of 12 of the 13 patients with primary IgA
nephropathy. Secretory component and J-chain could not be
demonstrated by routine procedures in the deposits of any of
the patients. The positive staining for i-chain, after pretreat-
ment of tissue sections with 6 M urea in glycine HC1 (pH 3.2),
agrees with previous reports [11, 13] and may be due to an
incomplete exposure of the antigenic sites of the i-chain in
untreated sections. The presence of J-chain and the fact that the
distribution pattern of the binding of human free secretory
component in the mesangium was identical to that observed for
IgA 1 together are indicative of the true dimer nature of the IgA
deposits. Although the presence of mesangial 1gM (in four
patients) could also have led to secretory component-binding,
the positive results found for patients without 1gM deposits and
the identical distribution of the IgA 1 and secretory component-
binding capacity in the mesangium argue against such a mecha-
nism in these cases. Circulating immune complexes will deposit
preferentially in a mesangial localization. Therefore, the surplus
of dimeric IgAl in the circulation and the presence of similar
material in the mesangium suggests a pathogenetic relationship.
Whether dimeric IgAl combines in the circulation with an
antigen to form an immune complex that is deposited in the
glomerular mesangium or is trapped by the mesangium either
without binding to an antigen or combining with a planted or
fixed antigen cannot be determined from our study. Dimeric
IgA 1 and IgA2 are thought to be produced mainly at secretory
sites. IgA produced in the bone marrow belongs predominantly
to the IgAl subclass. An appreciable number of IgA-positive
bone marrow cells contain, however, IgA in dimeric form [25].
This polymer IgA is supposed to be cleared rapidly from the
circulation [45]. The origin of the excess dimeric IgAl found in
our patients with primary IgA nephropathy is unclear but in
view of the lack of evidence of a defect at the secretory sites
[46] and the demonstration of the IgAl subclass in this study, a
bone marrow origin is favored. In humans, small to moderate
increases in the serum level of true dimeric IgA are likely to
reflect a defective clearance mechanism or a markedly in-
creased production due to unknown stimuli. Any of these
mechanisms could be operational in patients with primary IgA
nephropathy and may be genetically [47, 48] or geographically
[49] determined. In conclusion, this study shows that the IgA
found in mesangial deposits and the increase in circulating
polymeric IgA in patients with primary IgA nephropathy may
be attributed to an elevation of circulating dimeric IgAl.
Further studies are needed to detect the site of production of
this dimeric lgA 1.
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